The rest of the cascade

A man on testosterone therapy can have textbook labs and still feel like he is chasing something. Testosterone mid-range, estradiol in the window, everything the chart asks for. He adds hCG, and a few weeks later reports what the chart never promised: a steadier mood, a clearer head, drive and motivation the testosterone reading alone hadn’t restored. It is a common enough account in clinic and in the communities around testosterone use to deserve a mechanism rather than a shrug. It is also an odd one, because hCG is, in the clinic, a fertility drug. Why would relighting the testicle change how a man feels?

The honest answer runs through what replacement quietly costs. Topping up one hormone silences the gland that used to make it, and some of what that gland made was doing work no testosterone panel ever shows. What these men describe is, in the most defensible reading, what it feels like to get part of that back.

Testosterone therapy raises the level in your blood to target. The hypothalamus and pituitary read that high level and do what they are built to do: they stop sending the release signals. GnRH falls, the pituitary’s LH and FSH fall with it, and the Leydig cells of the testis lose the drive that keeps them working. Serum testosterone looks perfect on the draw. Inside the testis, the lights go out.

The scale of that is easy to underestimate. In a randomized study, giving men testosterone dropped their intratesticular testosterone by about 94 percent (Coviello et al., J. Clin. Endocrinol. Metab. 2005); adding a low dose of hCG, 250 IU every other day, held it in the normal range, and did so in a clean dose-response. Concentration is the reason it matters: a working testis runs at something like 50 to 100 times the testosterone level found in blood, and it uses that gradient to do far more than top up the circulation. A serum number is blind to all of it.

hCG is what lets you light the testis back up without waiting on the pituitary. It binds the same receptor LH does – the LH/choriogonadotropin receptor – so to a Leydig cell it reads as an LH signal. Nothing is added from outside. The cell is simply told to switch on again.

A Leydig cell is a small steroid factory, and testosterone is its final product, not its only one. The line runs from cholesterol through pregnenolone, into progesterone and 17-hydroxyprogesterone, on to androstenedione, then testosterone, and finally to estradiol by way of the aromatase enzyme. Drive the cell with LH or hCG and the whole line runs.

Exogenous testosterone delivers the last box on that line and nothing above it. Your body will still aromatize some of that testosterone into estradiol out in the periphery, so you are not left with none. But the pregnenolone and progesterone the testis used to make, and the estradiol it produced locally, all go missing while the factory is dark. The phrase in the title is meant literally. The rest of the cascade is a specific list of molecules, and several of them are active in the brain.

Pregnenolone and progesterone are the feedstock for a family of neuroactive steroids. The best known is allopregnanolone, a metabolite of progesterone that acts as a positive allosteric modulator of the GABA-A receptor, the brain’s main inhibitory channel. Its signature is calm: anxiolytic, settling, mood-steadying. This is well-trodden pharmacology, not a fringe claim. Allopregnanolone is the active principle of brexanolone and zuranolone, the two neurosteroids the FDA approved for postpartum depression, which is direct proof that a progesterone-derived steroid can move mood, and move it fast, through GABA-A.

From there the chain from testis to mood is coherent: restore Leydig-cell output, put more of the upstream steroid substrate back into circulation, and you supply more raw material for the neuroactive steroids that a dose of testosterone never touches.

The least speculative part of the story is estradiol. In men it is not a hormone to be merely tolerated; it is required for libido, erectile function, mood, and bone. The cleanest demonstration came from a controlled study that pried the two hormones apart: when men on fixed testosterone had aromatase blocked so estradiol couldn’t form, sexual desire and erectile function fell (Finkelstein et al., N. Engl. J. Med. 2013), an effect the authors traced to the missing estradiol rather than to testosterone.

Estradiol is a frequent casualty of the way therapy gets run. An over-eager aromatase inhibitor, or simply the loss of the testis’s own estrogen production, can leave a man with plenty of testosterone and too little estradiol: flat, low on libido, achy in the joints, low in mood. hCG restores aromatization inside the testis and brings estradiol, and the testosterone-to-estradiol balance, back up with it. A large share of “hCG made me feel human again” is probably this – and unlike the neurosteroid account, you can watch it happen on a lab draw.

Everything so far has been the Leydig cell’s story. The testis runs on two signals, though, not one, and they wake two different cells. LH drives the Leydig cell and its steroid cascade. FSH drives the Sertoli cell, the nurse cell of sperm production, which also makes inhibin B and runs its own aromatase inside the seminiferous tubule.

hCG stands in for LH, and only for LH. It relights the Leydig arm – the intratesticular testosterone, the steroid cascade, the estradiol – and leaves the Sertoli arm dark. That is why hCG keeps the testes full-sized and holds some sperm production, while a man who wants full fertility back, especially after a long shutdown, usually needs FSH as well.

That is where hMG earns its place. Human menopausal gonadotropin, or menotropin, is purified from urine and carries both LH and FSH activity in roughly equal measure – and in some modern preparations the LH half is literally supplied by added hCG. Recombinant FSH does the Sertoli job on its own. So the hormones sort cleanly by the cell they wake: hCG and LH light the Leydig, steroid-making arm; hMG and FSH light the Sertoli, fertility arm. GnRH and the estrogen-blocking SERMs sit higher up and wake both, by working through the pituitary rather than the testis.

Line the options up and they form a ladder, rung by rung, by how much of the system stays awake. What men describe as they climb it is less a matter of more testosterone than of more gland.

• Testosterone alone. The floor. Both arms dark, the testes idle, the axis silent. The serum number is right, and men still often describe a flatness, a sense of being switched off, sometimes a testicular emptiness or ache. Everything upstream of the injection goes unmade.
• Testosterone with hCG. The Leydig arm back on: intratesticular testosterone and the steroid cascade restored, the testes full. This is where the 'switched on again' reports cluster, from libido to drive to a steadier baseline. The catch is estradiol. hCG revives the testis's own aromatization, so some men swing high and have to manage it; the hormone that helps is also the one that can overshoot.
• hCG plus hMG or FSH. Both arms awake. Added mostly when fertility is the goal: sperm production, inhibin B, the fuller testicular ecosystem. What men report here is less a mood shift than a sense of completeness, the gland doing its whole job again rather than the steroid half alone.
• A SERM instead, enclomiphene or clomiphene. Skip the injections and lift the whole axis from the top by taking estrogen's brake off the pituitary: your own LH and FSH, pulsatile, fertility preserved. It works only if the pituitary is intact, and older clomiphene carries a long-lived estrogenic isomer that can bring its own mood and visual side effects. Enclomiphene is the cleaner cut.
• Pulsatile GnRH. The most faithful copy of physiology, restoring both gonadotropins in rhythm rather than as a steady dose. It needs a pump and an intact pituitary, so it stays largely a specialist tool, but it is the reference standard the rest of the ladder is only approximating.

The throughline is the one the piece keeps arriving at. Replacement hands you the hormone; each rung above it hands back more of the gland, and for some men more of the way they used to feel. Which rung fits is a clinical decision with real trade-offs at every step. None of this is a protocol, only the reasoning under one.

Not all of the reported benefit needs a steroid to explain it, and the sceptical reading is part of the honest one.

• Reassurance. hCG keeps the testes full-sized and fertility on the table. Men on testosterone alone often describe feeling switched off; men who add hCG describe feeling switched on. Some of that is mood following self-image rather than serum chemistry, which makes it no less real to the person living in it.
• Expectancy. hCG is usually added by a motivated man hoping for exactly this result, with no blinding and no control arm. Subjective wellbeing is the single endpoint most easily moved by anticipation.
• A bad setup, corrected. Some of the credit belongs to undoing an error — a crashed estradiol, an over-suppressed axis — rather than to anything hCG adds that is new. The improvement is genuine; the story a man tells about why can still be wrong.

The site’s creed – bullish on the science, sceptical on the page – sorts this cleanly. Graded by what the data will bear:

• Well established. hCG maintains intratesticular testosterone and testicular function while exogenous testosterone suppresses the axis, preserving testis size and fertility. This rests on randomized, dose-response human data (Coviello 2005).
• Settled, for fertility. Beyond maintaining intratesticular testosterone, adding FSH activity (as hMG or recombinant FSH) restores spermatogenesis, most clearly in hypogonadotropic hypogonadism. The division of labor between the LH and FSH arms is standard reproductive endocrinology, not conjecture.
• Well grounded. Estradiol is independently necessary for male libido, erectile function, and mood; restoring the testis's own estrogen output is a real, measurable route to feeling better (Finkelstein 2013).
• Plausible, not proven. A broader circulating steroid milieu — pregnenolone, progesterone, and the neuroactive steroids they feed — as a path to a steadier baseline. The biology is sound; no controlled trial has tested hCG-on-TRT against a mood endpoint.
• Confounded. The subjective 'mental benefit' reports are unblinded and uncontrolled, and they mix chemistry with reassurance, expectancy, and the quiet correction of bad protocols.
• Overclaimed before. hCG sold for wellbeing and weight loss was tested and came back negative (Lijesen 1995). The mood claim on TRT deserves the same standard, not a pass.

Set against all that, the reports make sense without any magic. Testosterone therapy hands you the one molecule the lab measures. hCG asks the gland to make the others again, and the brain had been quietly using some of them. Where the effect shows up on a chart, in estradiol and the balance around it, believe it. Where it doesn’t, in the neurosteroid milieu, hold both the curiosity and the scepticism: the mechanism is genuinely promising and genuinely unproven, and those are allowed to be true at once.

None of this is a recommendation. hCG and testosterone are prescription decisions with real trade-offs, and what you have just read is an account of mechanism, not a protocol.